Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO and ATRA +/- Mylotarg in Pediatric APL
NCT04793919Phase 2Recruiting
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Antibody-Drug Conjugates (ADCs)
- Countries
- 12
01
Overview
Phase 2, open-label trial of gemtuzumab ozogamicin, arsenic trioxide and tretinoin in acute promyelocytic leukemia (APL), sponsored by Italian Association of Pediatric Hematology and Oncology. Started Oct 2019; status: recruiting.
02
Drugs
gemtuzumab ozogamicinarsenic trioxidetretinoin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT04793919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793919.